Innovative NO Delivery | Beyond Air's LungFit PH system generates nitric oxide from room air, potentially disrupting the $700 million global market for NO delivery systems |
Financial Hurdles | Explore Beyond Air's strategy to overcome significant cash burn and reach cash flow breakeven by fiscal year 2027, despite lowered revenue projections |
Market Expansion Plans | Learn about Beyond Air's efforts to expand LungFit PH's approved uses, including a pending FDA decision for cardiac surgeries and pursuit of CE mark in Europe |
Competitive Landscape | Delve into Beyond Air's positioning against dominant players like Mallinckrodt, with analyst price target at $2.00 amid market challenges and opportunities |
Metrics to compare | XAIR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXAIRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −2.1x | −0.4x | |
PEG Ratio | 0.00 | −0.07 | 0.00 | |
Price/Book | 1.0x | 2.8x | 2.6x | |
Price / LTM Sales | 0.8x | 2.4x | 3.0x | |
Upside (Analyst Target) | - | 63.2% | 51.7% | |
Fair Value Upside | Unlock | 18.3% | 8.8% | Unlock |
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.